COVID-19
-
Serendipity And CDMO Catapult COVID-19 Candidate
7/14/2021
This gets filed in the scientific realm of: “Hey, look what we might have here?” A key ingredient for advanced, oral-solid-dose opioid medicines in clinical study, developed and manufactured with assistance from a reliable CDMO, turns out to have investigative potential for the treatment of COVID-19. Here’s how sponsor and service provider swung into action.
-
Pharma's Lack Of Leadership On Coronavirus Origins
6/2/2021
Pharma has a China problem. In at least one regard, it uncomfortably mirrors that of the media. But the media has (tentatively) begun a mea culpa of sorts. Should Pharma? An editorial on how Pharma has handled the (lack of a) Wuhan Coronavirus Lab investigation.
-
What Happens When IP is Redistributed? CDMOs Without Borders
5/24/2021
Would any respectable contract development or manufacturing organization agree to utilize intellectual property “waived” by the WTO or other body from a reputable innovator? We say no, and for valid reasons.
-
Did You Vote To Give Your IP Away?
5/19/2021
Unfortunately, the turmoil of the China-borne coronavirus, and the U.S. presidential election of 2020, continue to find new ways to impact us. A biopharma-industry patent lawyer walks us through some implications.
-
SPACs, Opioids, and COVID: Ensysce Biosciences Making “Virtual” History
5/10/2021
If Ensysce Biosciences were a ball of yarn, we’d be unwinding it for hundreds of miles from its location in La Jolla, California. We’d unravel solid oral dose programs – new opioids and a COVID treatment, an all-outsourced model, and now one of the first biotechs to go public via a SPAC (special purpose acquisition company).
-
Did The U.S. Government Just Hijack A CDMO?
4/14/2021
There are extenuating circumstances, but we need a deeper contemplation of what has gone on at Emergent BioSolutions regarding vaccine production. Outsourced Pharma readers are the experienced professionals to do that. So from that lens of supply-chain understanding, what’s happening here?
-
A Year Out: Time To Laud CDMOs For COVID-19 Efforts
4/6/2021
A biopharma executive believes the industry should receive a more complete rendering of what we’ve learned from our COVID-19 experience.His message is familiar, but isn't sufficiently elucidated: "Our drug development and manufacturing outsourcing model is integral to taming the pandemic."
-
Outsourcing Challenges For Emerging mRNA Biopharma
3/19/2021
Recent mRNA vaccine successes conceal the long-term challenges emerging mRNA companies have faced with finding experience and capacity at CDMOs. Here’s sound advice for emerging mRNA when forming scientific, investment, and overall plans for commercial success.
-
Nations Should Be Able To Take Care Of Their Own
3/10/2021
A Biopharma and CDMO lead a positive nationalism in Canada. In fact, ‘Canada First’ hasn’t the political corollaries felt by “America First” deliberations in the U.S. Jared Davis, CEO of Providence Therapeutics, believes every country should be able to take care of their own during a health-care crises.
-
Canadian Biopharma “Enables” CDMO For mRNA Vaccine Production
3/3/2021
An investigation into the amazing story of how an emerging mRNA Biopharma is “enabling” the creation of a CDMO for an “all-Canada” supply chain, for COVID-19 and precision medicines.